Clinical Trial: NCT04495153
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Candel Therapeutics, Inc. |
| Information Provided By: | Candel Therapeutics, Inc. |
| Last Update Posted: | 2025-08-22 |
Study Overview
Brief Summary
The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the clinical response is inadequate. CAN-2409 is a viral immunotherapy approach that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation. A combination of CAN-2409 added to standard of care (SOC) checkpoint inhibitors may lead to improved long-term outcomes for patients with NSCLC who have suboptimal response to ICI therapy.
Official Title
Conditions
Intervention / Treatment
- Biological: Aglatimagene besadenovec
Other Study ID Numbers
- LuTK02
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Candel Therapeutics, Inc. |
| Information Provided By: | Candel Therapeutics, Inc. |
| Last Update Posted: | 2025-08-22 |
Study Overview
Brief Summary
The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the clinical response is inadequate. CAN-2409 is a viral immunotherapy approach that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation. A combination of CAN-2409 added to standard of care (SOC) checkpoint inhibitors may lead to improved long-term outcomes for patients with NSCLC who have suboptimal response to ICI therapy.
Official Title
Conditions
Intervention / Treatment
- Biological: Aglatimagene besadenovec
Other Study ID Numbers
- LuTK02